{"id":16617,"date":"2024-02-28T10:18:38","date_gmt":"2024-02-28T01:18:38","guid":{"rendered":"https:\/\/www.hospital.pref.ibaraki.jp\/chuo\/?page_id=16617"},"modified":"2026-01-08T15:32:20","modified_gmt":"2026-01-08T06:32:20","slug":"results","status":"publish","type":"page","link":"https:\/\/www.hospital.pref.ibaraki.jp\/chuo\/department\/shinryoka\/ketunai\/results\/","title":{"rendered":"\u8840\u6db2\u5185\u79d1\u3000\u81e8\u5e8a\u7814\u7a76\u767a\u8868\u5b9f\u7e3e"},"content":{"rendered":"\n<h2 class=\"wp-block-heading\">\u5e73\u621028\u5e74\u5ea6\uff5e\u4ee4\u548c6\u5e74\u5ea6<\/h2>\n\n\n\n<h3 class=\"wp-block-heading\">\u4ee4\u548c6\u5e74\u5ea6<\/h3>\n\n\n\n<p>\u3010\u8ad6\u6587\u3011<\/p>\n\n\n\n<ol class=\"wp-block-list\">\n<li>Wang Y, Shimosaki S, Ikebe E, Iha H, Yamamoto J, Fife N, Ichikawa T, M Hori, Ogata M, T\u3000sukamoto Y, Hijiya N, Moriyama M, Hagiwara S, Kusano S, Saito M, Ahmed K, Nishizono A, Handa H, Morishita K\u00a0 IMiD\/CELMoD-induced growth suppression of adult T-cell leukemia\/lymphoma cells via cereblon through downregulation of target proteins and their downstream effectors Front Oncol. 2024 Jan 24;13:1272528.<\/li>\n\n\n\n<li>Kikuchi J, M. Hori, Osada N, Matsuoka S, Suzuki A, Kakugawa S, Yasui H, Harada T, Tenshin T, Abe M, Nakasone H, Furukawa Y Soluble SLAMF7 is generated by alternative splicing in multiple myeloma cells Haematologica Early view Jun 13, 2024<\/li>\n\n\n\n<li>Wang Y, Tsukamoto, Y.; M.Hori, Iha, H. Disulfidptosis: A Novel Prognostic Criterion and Potential Treatment Strategy for Diffuse Large B-Cell Lymphoma (DLBCL). Int. J. Mol. Sci. 2024, 25, 7156.<\/li>\n<\/ol>\n\n\n\n<p>\u3010\u5b66\u4f1a\u767a\u8868\u3011<\/p>\n\n\n\n<ol class=\"wp-block-list\">\n<li>\u5800\u5149\u96c4\u3001\u85e4\u5c3e\u9ad8\u884c\u3001\u9ed2\u5ddd\u5b89\u6e80\u3001\u9577\u8c37\u5ddd\u96c4\u4e00\u3001\u5c0f\u5cf6\u5bdb\u3001\u83c5\u8c37\u660e\u5fb3\u3001\u4e09\u6a4b\u5f70\u4e00\u3001\u77f3\u9ed2\u613c\u543e\uff0e\u5358\u4e00\u65bd\u8a2d\u306b\u304a\u3051\u308b\u30a8\u30ed\u30c4\u30ba\u30de\u30d6\u306e\u9577\u671f\u6cbb\u7642\u304c\u53ef\u80fd\u3060\u3063\u305f\u75c7\u4f8b\u306b\u3064\u3044\u3066\u306e\u691c\u8a0e\uff0e\u7b2c86\u56de\u65e5\u672c\u8840\u6db2\u5b66\u4f1a\u5b66\u8853\u96c6\u4f1a\u30012024.10(\u4eac\u90fd)<\/li>\n\n\n\n<li>\u85e4\u5c3e\u9ad8\u884c\u3001\u9577\u8c37\u5ddd\u96c4\u4e00\u3001\u9ed2\u5ddd\u5b89\u6e80 \u3001\u5800\u5149\u96c4 \uff0e\u5f53\u9662\u306b\u304a\u3051\u308bPTCL\u6cbb\u7642\u306e\u73fe\u72b6\uff0e\u7b2c86\u56de\u65e5\u672c\u8840\u6db2\u5b66\u4f1a\u5b66\u8853\u96c6\u4f1a\u30012024.10(\u4eac\u90fd)<\/li>\n<\/ol>\n\n\n\n<h3 class=\"wp-block-heading\">\u4ee4\u548c5\u5e74\u5ea6<\/h3>\n\n\n\n<p>\u3010\u8457\u66f8\u3011<\/p>\n\n\n\n<ol class=\"wp-block-list\">\n<li>\u9577\u8c37\u5ddd\u96c4\u4e00\u3001\u8840\u6db2\u75c7\u5019\u7fa4\uff08\u7b2c3\u7248\uff09\uff08III\uff09\u65e5\u672c\u81e8\u5e8a\u793e\u3000\u6771\u4eac\u30002023\u3001p72-75\u3000\u507d\u6027\u8840\u5c0f\u677f\u6e1b\u5c11\u75c7\u3000<\/li>\n<\/ol>\n\n\n\n<p>\u3010\u8ad6\u6587\u3011<\/p>\n\n\n\n<ol class=\"wp-block-list\">\n<li>Elotuzumab Plus Pomalidomide and Dexamethasone for Relapsed\/Refractory Multiple Myeloma: Final Overall Survival Analysis From the Randomized Phase II ELOQUENT-3 Trial. Dimopoulos MA, Dytfeld D, Grosicki S, Moreau P, Takezako N\u3001 M. Hori,\u3001Leleu X,\u3001LeBlanc R\u3001Suzuki K\u3001Raab MS, Richardson PG, Popa McKiver M, Jou YM, Yao D, Das P, San-Miguel J. J Clin Oncol. 2023 Jan 20;41(3):568-578<em>.<\/em><\/li>\n\n\n\n<li><a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/36929591\/\">Five-year follow-up of a phase II study of&nbsp;DA-EPOCH-R&nbsp;with high-dose MTX in CD5-positive DLBCL.<\/a>Miyazaki K\u3001Sakai R\u3001Iwaki N\u3001amamoto G,\u3001urayama K\u3001Nishikori M,\u3001unami K,\u3001oshida I,\u3001ano H\u3001Takahashi N\u3001 Okamoto A\u3001 Munemoto S\u3001 Sawazaki A\u3001 Suehiro Y\u3001 Fukuhara N\u3001 Wake A\u3001 Arai A\u3001 Masaki Y\u3001oyama K\u3001Yokoyama A,\u3001sunemine H\u3001asegawa Y\u3001tsumoto K\u3001amada T\u3001ishimura Y\u3001Tamaru S\u3001sano N\u3001Miyawaki K\u3001Izutsu K\u3001inoshita T\u3001uzuki R\u3001Ohshima K\u3001ato K\u3001atayama N\u3001amaguchi M\u3001Cancer Sci. 2023 Jun;114(6):2689-2691.<\/li>\n<\/ol>\n\n\n\n<h3 class=\"wp-block-heading\">\u4ee4\u548c4\u5e74\u5ea6<\/h3>\n\n\n\n<p>\u3010\u8457\u66f8\u3011<\/p>\n\n\n\n<ol class=\"wp-block-list\">\n<li>\u6b6f\u79d1\u533b\u9662\u306e\u305f\u3081\u306e\u5185\u79d1\u5b66\u8b1b\u5ea7\u3000\u5168\u8eab\u7ba1\u7406\u30fb\u5168\u8eab\u75be\u60a3\u3092\u898b\u636e\u3048\u305f\u88dc\u7db4\u6cbb\u7642\u306e\u30b9\u30b9\u30e1(\u7b2c44\u56de)\u300c\u6765\u9662\u60a3\u8005\u304c\u8ca7\u8840!?\u3000\u8ca7\u8840\u306e\u539f\u56e0\u3068\u75c7\u72b6\u30fb\u5206\u985e\u3092\u77e5\u308a\u3001\u95a2\u9023\u3059\u308b\u820c\u306e\u75be\u60a3\u3068\u6b6f\u79d1\u533b\u7642\u306b\u3064\u3044\u3066\u5b66\u307c\u3046\u300d\u9577\u8c37\u5ddd\u96c4\u4e00,\u5c71\u7e23\u61b2\u53f8,\u5c0f\u5cf6 \u5bdb,\u67f3\u5ddd \u5fb9 \u88dc\u7db4\u81e8\u5e8a\/\u533b\u6b6f\u85ac\u51fa\u7248\u682a\u5f0f\u4f1a\u793e\/pp.294-316, 2022-05<\/li>\n<\/ol>\n\n\n\n<p>\u3010\u8ad6\u6587\u3011<\/p>\n\n\n\n<ol class=\"wp-block-list\">\n<li>Administration of brentuximab vedotin to a Hodgkin lymphoma patient with liver dysfunction due to vanishing bile duct syndrome resulting in a partial response without any severe adverse events.Kantaro Ishitsuka, Yasuhisa Yokoyama , Naoko Baba, Ryota Matsuoka, Noriaki Sakamoto, Tatsuhiro Sakamoto, Manabu Kusakabe, Takayasu Kato, Naoki Kurita, Hidekazu Nishikii, Mamiko Sakata-Yanagimoto, Naoshi Obara, Yuichi Hasegawa, Shigeru Chiba Journal of Clinical and Experimental Hematopathology 62:3;154-157, 2022<\/li>\n\n\n\n<li>Novel translocation of POGZ\/STK11 in de novo mast cell leukemia with KIT D816H mutation. Kantaro Ishitsuka, Yuki Yoshizawa, Hidekazu Nishikii, Manabu Kusakabe, Yufu Ito, Yukinori Inadome, Tatsuhiro Sakamoto, Takayasu Kato, Naoki Kurita,Yasuhisa Yokoyama, Naoshi Obara, Yuichi Hasegawa, Yasuhito Nannya, Seishi Ogawa, Mamiko Sakata-Yanagimoto,Shigeru Chiba Leukemia Lymhoma 63:14;3475-3479, 2022<\/li>\n<\/ol>\n\n\n\n<p>\u3010\u5b66\u4f1a\u767a\u8868\u3011<\/p>\n\n\n\n<ol class=\"wp-block-list\">\n<li>Clinical significance of SLAMF7 expression in AITL T. Fujio, Y. Hasegawa, Y.Kurokawa, H. Kojima, M. Hori \u8328\u57ce\u770c\u7acb\u4e2d\u592e\u75c5\u9662 \u8840\u6db2\u5185\u79d1, \u816b\u760d\u5185\u79d1 \u7b2c84\u56de\u65e5\u672c\u8840\u6db2\u5b66\u4f1a\u5b66\u8853\u7dcf\u4f1a\u30002022\u5e7410\u670814\u65e5\u3000\u798f\u5ca1\u56fd\u969b\u4f1a\u8b70\u5834<\/li>\n\n\n\n<li>Elotuzumab\/pomalidomide\/dexamethasone in Japanese patients with RRMM: final OS from ELOQUENT-3 1.\u4f0a\u85e4 \u85ab\u6a39, 2.\u5800 \u5149\u96c4, 3.\u7af9\u8feb \u76f4\u6a39, 4.\u89d2\u5357 \u4e00\u8cb4, 5.\u9ed2\u7530 \u7d14\u4e5f, 6.Mihaela Popamckiver, Oumar Sy, 7.\u4e09\u597d \u660c\u53f2, 8.\u9234\u6728 \u61b2\u53f2 \u7b2c84\u56de\u65e5\u672c\u8840\u6db2\u5b66\u4f1a\u5b66\u8853\u7dcf\u4f1a\u30002022\u5e7410\u670814\u65e5\u3000\u798f\u5ca1\u56fd\u969b\u4f1a\u8b70\u5834<\/li>\n\n\n\n<li>\u5408\u540c\u8f38\u8840\u7642\u6cd5\u59d4\u54e1\u4f1a\u3000\u59d4\u54e1\u9577\u306e\u7acb\u5834\u304b\u3089\u300c\u90fd\u9053\u5e9c\u770c\u5408\u540c\u8f38\u8840\u7642\u6cd5\u59d4\u54e1\u4f1a\u306e\u904b\u55b6\u306b\u3042\u305f\u308a\u611f\u3058\u3066\u3044\u308b\u8ab2\u984c\u3068\u63d0\u6848 \u9577\u8c37\u5ddd \u96c4\u4e00 \u65e5\u672c\u8f38\u8840\u30fb\u7d30\u80de\u6cbb\u7642\u5b66\u4f1a\u3000\u79cb\u5b63\u30b7\u30f3\u30dd\u30b8\u30a6\u30e0\/2022\u5e7410\u670829\u65e5\u3000\u65b0\u5bbf\u4f4f\u53cb\u30db\u30fc\u30eb<\/li>\n<\/ol>\n\n\n\n<h3 class=\"wp-block-heading\">\u4ee4\u548c3\u5e74\u5ea6<\/h3>\n\n\n\n<p>\u3010\u8ad6\u6587\u3011<\/p>\n\n\n\n<ol class=\"wp-block-list\">\n<li>Allogeneic hematopoietic stem cell transplantation for adult patients with B-cell acute lymphoblastic leukemia with high hyperdiploidy: a retrospective nationwide study. Kurosawa S, Kaito S, Uchida N, Fukuda T, Doki N, Mori T,&nbsp;Hasegawa Y, Takada S, Sakaida E, Tanaka M, Ikegame K, Kanda J, Atsuta Y, Kako S.Leuk Lymphoma. 2021 Oct;62(10):2514-2520.&nbsp;<\/li>\n\n\n\n<li>The Japanese Medical Science Federation COVID-19 Expert Opinion English Version. JMA J 4(2):148-162, Apr 15, 2021 Nangaku M, Kadowaki T, Yotsuyanagi H, Ohmagari N, Egi M, Sasaki J, Sakamoto T, Hasegawa Y, Ogura T, Chiba S, Node K, Suzuki R, Yamaguchi Y, Murashima A, Ikeda N, Morishita E, Yuzawa K, Moriuchi H, Hayakawa S, Nishi D, Irisawa A, Miyamoto T, Suzuki H, Sone H, Fujino Y.<\/li>\n\n\n\n<li>Salvage Cord Blood Transplantation Using a Short-term Reduced-intensity Conditioning Regimen for Graft Failure. Intern Med (doi: 10.2169\/internalmedicine.7836-21. Suma S, Yokoyama Y, Momose H, Makishima K, Kiyoki Y, Sakamoto T, Kusakabe M, Kato T, Kurita N, Nishikii H, Sakata-Yanagimoto M, Obara N, Hasegawa Y, Chiba S.<\/li>\n\n\n\n<li>Allogeneic hematopoietic stem cell transplantation for adult patients with B-cell acute lymphoblastic leukemia with high hyperdiploidy: a retrospective nationwide study. Leuk Lymphoma 62(10):2514-2520, Oct, 2021 Kurosawa S, Kaito S, Uchida N, Fukuda T, Doki N, Mori T, Hasegawa Y, Takada S, Sakaida E, Tanaka M, Ikegame K, Kanda J, Atsuta Y, Kako S.<\/li>\n\n\n\n<li>Early administration of cyclosporine may reduce the incidence of cytokine release syndrome after HLA-haploidentical hematopoietic stem-cell transplantation with post-transplant cyclophosphamide. Ann Hematol 100(5):1295-1301, May, 2021 Kurita N, Sakamoto T, Kato T, Kusakabe M, Yokoyama Y, Nishikii H, Sakata-Yanagimoto M, Obara N, Hasegawa Y, Chiba S.<\/li>\n\n\n\n<li>\u5f8c\u5929\u6027\u8840\u5c0f\u677f\u6a5f\u80fd\u7570\u5e38\u306b\u3088\u308b\u8457\u660e\u306a\u51fa\u8840\u50be\u5411\u3092\u5448\u3057\u305ftriple negative\u539f\u767a\u6027\u9aa8\u9ac4\u7dda\u7dad\u75c7 \u81e8\u5e8a\u8840\u6db262(9):1406-1411\u767e\u702c\u6625\u4f73\uff0c\u9326\u4e95\u79c0\u548c\uff0c\u4e0a\u59bb\u884c\u5247\uff0c\u592a\u7530\uff08\u5824\uff09\u80b2\u4ee3\uff0c\u5357\u8c37\u6cf0\u4ec1\uff0c\u5409\u7530\u8fd1\u601d\uff0c\u7c73\u91ce\u7422\u54c9\uff0c\u65e5\u4e0b\u90e8\u5b66\uff0c\u6a2a\u5c71\u6cf0\u4e45\uff0c\u52a0\u85e4\u8cb4\u5eb7\uff0c\u6817\u7530\u5c1a\u6a39\uff0c\u4e94\u6708\u5973\u793c\u4e43\uff0c\u5742\u7530\uff08\u67f3\u5143\uff09\u9ebb\u5b9f\u5b50\uff0c\u5c0f\u539f \u76f4\uff0c\u9577\u8c37\u5ddd\u96c4\u4e00\uff0c\u5c0f\u5ddd\u8aa0\u53f8\uff0c\u5343\u8449 \u6ecb\u5f8c\u5929\u6027\u8840\u5c0f\u677f\u6a5f\u80fd\u7570\u5e38\u306b\u3088\u308b\u8457\u660e\u306a\u51fa\u8840\u50be\u5411\u3092\u5448\u3057\u305ftriple negative\u539f\u767a\u6027\u9aa8\u9ac4\u7dda\u7dad\u75c7 \u81e8\u5e8a\u8840\u6db262(9):1406-1411<\/li>\n\n\n\n<li>\u6297CD38\u6297\u4f53\u6cbb\u7642\u306b\u304a\u3051\u308b\u8f38\u8840\u691c\u67fb\u4e0a\u306e\u554f\u984c\u70b9\u3068\u5bfe\u51e6\u6cd5\u306b\u95a2\u3059\u308b\u591a\u65bd\u8a2d\u5171\u540c\u7814\u7a76\u65e5\u672c\u8f38\u8840\u7d30\u80de\u6cbb\u7642\u5b66\u4f1a\u8a8c67\uff083\uff09\uff1a440-448 \u5c71\u7530\u5343\u4e9c\u5e0c, \u7af9\u4e0b\u660e\u88d5, \u674e \u653f\u6a39, \u9577\u8c37\u5ddd\u96c4\u4e00, \u5927\u53cb\u76f4\u6a39, \u4e07\u6728\u7d00\u7f8e\u5b50, \u674e \u60a6\u5b50, \u540d\u5009 \u8c4a, \u65e5\u9ad8\u967d\u5b50, \u5ddd\u7551\u7d79\u4ee3, \u9053\u91ce\u6df3\u5b50, \u677e\u6d66\u79c0\u54f2, \u7be0\u539f \u8302, \u5c0f\u5d8b\u4fca\u4ecb, \u5965\u7530 \u8aa0, \u5c0f\u5e61\u7531\u4f73\u5b50<\/li>\n<\/ol>\n\n\n\n<p>\u3010\u5b66\u4f1a\u767a\u8868\u3011<\/p>\n\n\n\n<ol class=\"wp-block-list\">\n<li>\u53e3\u6f14<br>Clinical presentation of thrombocytosis: A single-center retrospective study of 1,202 patients<br>\u25cbYoko Edahiro1,2,3\uff0cYasumitsu Kurokawa1,4\uff0cSoji Morishita2, Marito Araki2,3,5\uff0cJun Ando1,5\uff0cNorio Komatsu1,2,3(Department of Hematology, Juntendo University, Tokyo, Japan1\uff0cDevelopment of Therapies Against MPN, Juntendo University, Tokyo, Japan2\uff0cDepartment of Advanced Hematology, Juntendo University, Tokyo, Japan3\uff0cHematol., Ibaraki Prefectural Central Hospital, Ibaraki, Japan4\uff0cTransfusion medicine and stem cell regulation, Juntendo University, Tokyo, Japan5)<\/li>\n\n\n\n<li>\u7b2c83\u56de\u65e5\u672c\u8840\u6db2\u5b66\u4f1a\u5b66\u8853\u96c6\u4f1a\u30002021\u5e749\u670823\u65e5\u3000web\u958b\u50ac<\/li>\n\n\n\n<li>\u30dd\u30b9\u30bf\u30fc<br>Elotuzumab plus pomalidomide\/dexamethasone for relapsed\/refractory multiple myeloma: final overall survival from the phase 2 ELOQUENT-3 trial Meletios A Dimopoulos, Dominik Dytfeld, Sebastian Grosicki, Philippe Moreau, Naoki Takezako, Mitsuo Hori, Xavier Leleu, Richard LeBlanc, Kenshi Suzuki,Marc S Raab,Paul G Richardson, Mihaela Popa McKiver, Ying-Ming Jou,David Yao, Prianka Das, Jes\u00fas San-Miguel<br>18th International Myeloma Workshop, September 8-11, 2021, Vienna, Austria<\/li>\n<\/ol>\n\n\n\n<h3 class=\"wp-block-heading\">\u4ee4\u548c2\u5e74\u5ea6<\/h3>\n\n\n\n<p>\u3010\u8ad6\u6587\u3011<\/p>\n\n\n\n<ol class=\"wp-block-list\">\n<li>Soluble SLAMF7 is a predictive biomarker for elotuzumab therapy. Suzuki A, Kakugawa S, Miyoshi M, Hori M, Suzuki K, Furukawa Y, Ohta K.Leukemia. 2020 Nov;34(11):3088-3090.<\/li>\n\n\n\n<li>Differences among hemoglobin thresholds for red blood cell transfusions in patients with hematological diseases in teaching hospitals: a real world data in Japan. Yokohama A, Okuyama Y, Ueda Y, Itoh M, Fujiwara SI, Hasegawa Y, Nagai K, Arakawa K, Miyazaki K, Makita M, Watanabe M, Ikeda K, Tanaka A, Fujino K, Matsumoto M, Makino S, Kino S, Takeshita A, Muroi K.Int J Hematol. 2020 Oct;112(4):535-543.<\/li>\n<\/ol>\n\n\n\n<p>\u3010\u5b66\u4f1a\u767a\u8868\u3011<\/p>\n\n\n\n<ol class=\"wp-block-list\">\n<li>\u30dd\u30b9\u30bf\u30fc<br>MDS\uff0cAML \u60a3\u8005\u306b\u5bfe\u3059\u308b azacytidine\uff0cCAG \u7642\u6cd5\u306e\u9023\u7d9a\u7684\u6cbb\u7642\u306e\u52b9\u679c<br>\u85e4\u5c3e \u9ad8\u884c\uff0c\u5800 \u5149\u96c4\uff0c\u5927\u8d8a \u9756\uff0c\u9ed2\u5ddd \u5b89\u6e80\uff0c\u83c5\u8c37 \u660e\u5fb3\uff0c\u77f3\u9ed2 \u613c\u543e\uff0c\u4e09\u6a4b \u5f70\u4e00\uff0c\u5c0f\u5cf6 \u5bdb<\/li>\n<\/ol>\n\n\n\n<p>\u3010\u8b1b\u6f14\u3011<\/p>\n\n\n\n<ol class=\"wp-block-list\">\n<li>\u53ef\u6eb6\u578b SLAMF7 \u306f\u9aa8\u9ac4\u816b\u7d30\u80de\u8868\u9762\u306e SLAMF7 \u3068\u306e\u7d50\u5408\u3092\u4ecb\u3057\u3066\u5897\u6b96\u4fc3\u9032\u306b\u50cd\u304f<br>\u83ca\u6c60 \u6b21\u90ce\uff0c\u5800 \u5149\u96c4\uff0c\u4f0a\u6ce2 \u82f1\u514b\uff0c\u53cd\u753a \u5178\u5b50\uff0c\u8429\u539f \u5c07\u592a\u90ce(\u9ed2\u7530 \u82b3\u660e\uff0c\u5c0f\u5c71 \u5927\u8f14\uff0c\u548c\u6cc9 \u900f\uff0c\u5b89\u4e95 \u5bdb\uff0c\u9234\u6728 \u6566\uff0c\u53e4\u5ddd \u96c4\u7950<\/li>\n\n\n\n<li>\u30ec\u30ca\u30ea\u30c9\u30df\u30c9\u306b\u3088\u308b ATL \u7d30\u80de\u5897\u6b96\u6291\u5236\u52b9\u679c\u306e\u5206\u5b50\u6a5f\u5e8f<br>\u4f0a\u6ce2 \u82f1\u514b\uff0c\u6c60\u8fba \u8a60\u7f8e\uff0c\u4e0b\u5d0e \u4fca\u4ecb\uff0c\u5c71\u672c \u6df3\u4e00\uff0c\u534a\u7530 \u5b8f\uff0c\u5800 \u5149\u96c4\uff0c\u9577\u8c37\u5ddd \u5bdb\u96c4\uff0c\u6ce5\u8c37 \u76f4\u6a39\uff0c\u585a\u672c \u7fa9\u4e4b\uff0c\u5b88\u5c71 \u6b63\u80e4\uff0c\u8349\u91ce \u79c0\u4e00\uff0c\u83ca\u6c60 \u6b21\u90ce\uff0c\u53e4\u5ddd \u96c4\u7950\uff0c\u8429\u539f \u5c07\u592a\u90ce\uff0c\u658e\u85e4 \u76ca\u6e80\uff0c\u9234\u6728 \u6566\uff0c\u68ee\u4e0b \u548c\u5e83<\/li>\n\n\n\n<li>\u30c8\u30ed\u30f3\u30dc\u30dd\u30a8\u30c1\u30f3\u53d7\u5bb9\u4f53\u4f5c\u52d5\u85ac\u6cbb\u7642\u3092\u53d7\u3051\u305f\u518d\u751f\u4e0d\u826f\u6027\u8ca7\u8840\u60a3\u8005\u306e\u9aa8\u9ac4\u7d30\u80de\u306b\u304a\u3051\u308b\u907a\u4f1d\u5b50\u5909\u7570\u306e\u691c\u8a0e<br>\u5742\u672c \u7adc\u5f18\uff0c\u5c0f\u539f \u76f4\uff0c\u5357\u8c37 \u6cf0\u4ec1\uff0c\u65e5\u4e0b\u90e8 \u5b66(\uff0c\u52a0\u85e4 \u8cb4\u5eb7(Takayasu Kato)\uff0c\u6817\u7530 \u5c1a\u6a39\uff0c\u6a2a\u5c71 \u6cf0\u4e45\uff0c\u9326\u4e95 \u79c0\u548c\uff0c\u5742\u7530\uff08\u67f3\u5143\uff09 \u9ebb\u5b9f\u5b50\uff0c \u9577\u8c37\u5ddd \u96c4\u4e00\uff0c\u5c0f\u5ddd \u8aa0\u53f8\uff0c\u5343\u8449 \u6ecb<\/li>\n\n\n\n<li>Gilteritinib \u3092\u7528\u3044\u305f FLT3-ITD \u967d\u6027 AML \u306e\u5f53\u9662\u306b\u304a\u3051\u308b\u6cbb\u7642\u6210\u7e3e<br>\u5409\u6fa4 \u6709\u7d00\uff0c\u52a0\u85e4 \u8cb4\u5eb7\uff0c\u69c7\u5cf6 \u5065\u4e00\uff0c\u5742\u672c \u7adc\u5f18\uff0c\u6817\u7530 \u5c1a\u6a39\uff0c\u65e5\u4e0b\u90e8 \u5b66\uff0c\u6a2a\u5c71 \u6cf0\u4e45\uff0c\u9326\u4e95 \u79c0\u548c\uff0c\u5742\u7530\uff08\u67f3\u5143\uff09 \u9ebb\u5b9f\u5b50\uff0c\u5c0f\u539f \u76f4\uff0c\u9577\u8c37\u5ddd \u96c4\u4e00\uff0c\u5343\u8449 \u6ecb<\/li>\n\n\n\n<li>\u5f53\u9662\u306e\u81cd\u5e2f\u8840\u79fb\u690d\u306b\u304a\u3051\u308b\u524d\u51e6\u7f6e\u306e\u5f8c\u65b9\u8996\u7684\u89e3\u6790<br>\u98ef\u6751 \u767e\u840c\uff0c\u6817\u7530 \u5c1a\u6a39\uff0c\u5742\u672c \u7adc\u5f18\uff0c\u52a0\u85e4 \u8cb4\u5eb7\uff0c\u65e5\u4e0b\u90e8 \u5b66\uff0c\u6a2a\u5c71 \u6cf0\u4e45\uff0c\u9326\u4e95 \u79c0\u548c\uff0c\u5742\u7530\uff08\u67f3\u5143\uff09\u9ebb\u5b9f\u5b50\uff0c\u5c0f\u539f \u76f4\uff0c\u9577\u8c37\u5ddd \u96c4\u4e00\uff0c\u5343\u8449 \u6ecb \u4ee5\u4e0a \u7b2c 82 \u56de\u65e5\u672c\u8840\u6db2\u5b66\u4f1a\u5b66\u8853\u96c6\u4f1a 2020 \u5e74 10 \u6708 9\u221211 \u65e5 \u56fd\u7acb\u4eac\u90fd\u56fd\u969b\u4f1a\u9928<\/li>\n<\/ol>\n\n\n\n<h3 class=\"wp-block-heading\">\u4ee4\u548c\u5143\u5e74\u5ea6<\/h3>\n\n\n\n<p>\u3010\u8ad6\u6587\u3011<\/p>\n\n\n\n<ol class=\"wp-block-list\">\n<li>Elotuzumab plus lenalidomide and dexamethasone for newly diagnosed multiple myeloma: a<br>randomized, open-label, phase 2 study in Japan.Kubo K, Hori M, Ohta K, Handa H, Hatake K,<br>Matsumoto M, Hagiwara S, Ohashi K, Nakaseko C, Suzuki K, Ito S, Kinoshita G, Shelat SG, Miyoshi<br>M, Takezako N.Int J Hematol. 2020 Jan;111(1):65-74. Epub 2019 Nov 7.<\/li>\n<\/ol>\n\n\n\n<p>\u3010\u5b66\u4f1a\u767a\u8868\u3011<\/p>\n\n\n\n<ol class=\"wp-block-list\">\n<li>\u521d\u767a\u591a\u767a\u6027\u9aa8\u9ac4\u816b\u306b\u5bfe\u3059\u308b elotuzumab\/Ld \u4f75\u7528\u7642\u6cd5\uff1a\u65e5\u672c\u4eba\u60a3\u8005\u89e3\u6790 \u592a\u7530\u5065\u4ecb, \u5800 \u5149\u96c4, \u534a\u7530 \u5bdb, \u6728\u4e0b \u5143, Suresh Shelat, \u4e09\u597d\u660c\u53f2, \u7af9\u8feb\u76f4\u6a39, \u4e45\u4fdd\u6052\u660e(1.\u5927\u962a\u5e9c\u6e08\u751f \u4f1a\u4e2d\u6d25\u75c5\u9662 \u8840\u6db2\u5185\u79d1, 2.LIGARE \u8840\u6db2\u5185\u79d1\u592a\u7530\u30af\u30ea\u30cb\u30c3\u30af, 3.\u8328\u57ce\u770c\u7acb\u4e2d\u592e\u75c5\u9662 \u8840\u6db2\u5185\u79d1, 4.\u7fa4\u99ac \u5927\u5b66\u533b\u5b66\u90e8\u9644\u5c5e\u75c5\u9662\u8840\u6db2\u5185\u79d1, 5.\u30d6\u30ea\u30b9\u30c8\u30eb\u30fb\u30de\u30a4\u30e4\u30fc\u30ba \u30b9\u30af\u30a4\u30d6\u682a\u5f0f\u4f1a\u793e, 6.Bristol-Myers Squibb, 7.\u56fd\u7acb\u75c5\u9662\u6a5f\u69cb\u707d\u5bb3\u533b\u7642\u30bb\u30f3\u30bf\u30fc \u8840\u6db2\u5185\u79d1, 8.\u9752\u68ee\u770c\u7acb\u4e2d\u592e\u75c5\u9662 \u8840\u6db2\u5185\u79d1)<\/li>\n\n\n\n<li>\u518d\u767a\u30fb\u96e3\u6cbb\u6027\u591a\u767a\u6027\u9aa8\u9ac4\u816b\u306b\u5bfe\u3059\u308b elotuzumab\/Pd \u4f75\u7528\u7642\u6cd5\uff1aELOQUENT-3 \u8a66\u9a13\u65e5 \u672c\u4eba\u30b5\u30d6\u89e3\u6790 \u4f0a\u85e4\u85ab\u6a39, \u5800 \u5149\u96c4, \u7af9\u8feb\u76f4\u6a39, \u89d2\u5357\u4e00\u8cb4, \u9ed2\u7530\u7d14\u4e5f, Mihaela Popamckiver, Yingming Jou, Suresh Shelat, \u4e09\u597d \u660c\u53f2, \u9234\u6728 \u61b2\u53f2(1.\u5ca9\u624b\u533b\u79d1\u5927\u5b66\u9644\u5c5e\u75c5\u9662 \u81e8\u5e8a\u816b\u760d\u79d1, 2.\u8328\u57ce\u770c\u7acb\u4e2d\u592e\u75c5\u9662\u8840\u6db2\u5185\u79d1, 3.\u56fd\u7acb\u75c5\u9662\u6a5f\u69cb \u707d\u5bb3\u533b\u7642\u30bb\u30f3\u30bf\u30fc \u8840\u6db2\u5185\u79d1, 4.\u56fd\u7acb\u75c5\u9662\u6a5f\u69cb \u5ca1\u5c71\u533b\u7642\u30bb\u30f3\u30bf\u30fc \u8840\u6db2\u5185\u79d1, 5.\u4eac\u90fd \u5e9c\u7acb\u533b\u79d1\u5927\u5b66 \u8840\u6db2\u5185\u79d1\u90e8\u9580, 6.Bristol-Myers Squibb, 7.\u30d6\u30ea\u30b9\u30c8\u30eb\u30fb\u30de\u30a4\u30e4\u30fc\u30ba \u30b9\u30af\u30a4\u30d6\u682a\u5f0f\u4f1a \u793e, 8.\u65e5\u672c\u8d64\u5341\u5b57\u793e\u533b\u7642\u30bb\u30f3\u30bf\u30fc \u8840\u6db2\u5185\u79d1)\u7b2c 81 \u56de\u65e5\u672c\u8840\u6db2\u5b66\u4f1a\u5b66\u8853\u7dcf\u4f1a 2019 \u5e7410 \u6708 12 \u65e5 \u6771\u4eac\u30d5\u30a9\u30fc\u30e9\u30e0<\/li>\n<\/ol>\n\n\n\n<p>\u3010\u8b1b\u6f14\u3011<\/p>\n\n\n\n<ol class=\"wp-block-list\">\n<li>anti SLAMF-7 \u6297\u4f53\u3092\u7528\u3044\u305f\u591a\u767a\u6027\u9aa8\u9ac4\u816b\u306e\u6cbb\u7642\u306b\u3064\u3044\u3066-anti SLAMF-7 \u306f\u306a\u304b\u306a\u304b\u8208\u5473\u6df1\u3044\u6cbb\u7642 \u85ac\u3060\u3063\u305f\u306e\u3067\u3059-Treatment of multiple myeloma with anti SLAMF-7 antibody.The anti SLAMF7 antibody was quite an interesting drug.\u718a\u672c\u5927\u5b66\u533b\u5b66\u90e8\u5927\u5b66\u9662\u30bb\u30df\u30ca\u30fc 2019 \u5e74 11 \u6708 21 \u65e5 \u718a\u672c\u5927\u5b66\u30d2\u30c8\u30ec\u30c8\u30ed\u30a6\u30a4\u30eb\u30b9\u5b66\u5171\u540c\u7814\u7a76\u30bb\u30f3\u30bf\u30fc<\/li>\n<\/ol>\n\n\n\n<h3 class=\"wp-block-heading\">\u5e73\u621030\u5e74\u5ea6<\/h3>\n\n\n\n<p>\u3010\u8ad6\u6587\u3011<\/p>\n\n\n\n<ol class=\"wp-block-list\">\n<li>Dimopoulos MA, Dytfeld D, Grosicki S, Moreau P, Takezako N, Hori M, Leleu X, LeBlanc R, Suzuki K, Raab MS, Richardson PG, Popa McKiver M, Jou YM, Shelat SG, Robbins M, Rafferty B, San-Miguel J. Elotuzumab plus Pomalidomide and Dexamethasone for Multiple Myeloma. N Engl J Med. 379(19):1811-1822, 2018.<\/li>\n\n\n\n<li>Kajikawa N, Seki Y, Fujio T, Okoshi Y, Hori M, Saito H, Iijima T, Kojima H.Central nervous system<br>lymphoma harboring the JAK2 V617F mutation that developed after a 20-year history of polycythemia<br>vera. Intern Med. 57(22): 3293-3297, 2018<\/li>\n\n\n\n<li>Inada K, Okoshi Y, Cho-Isoda Y, Ishiguro S, Suzuki H, Oki A, Tamaki Y, Shimazui T, Saito H, Hori M, Iijima T, Kojima H. Endogenous reference RNAs for microRNA quantitation in formalin-fixed, paraffin-embedded lymph node tissue. Sci Rep. 8(1): 5918-5927, 2018.<\/li>\n<\/ol>\n\n\n\n<p>\u3010\u5b66\u4f1a\u767a\u8868\u3011<\/p>\n\n\n\n<ol class=\"wp-block-list\">\n<li>Hori M, Takezako N, Sunami K, Ito S, Kuroda J, Mihaela Popa McKiver, Jou Y-M, Suresh G. Shelat,<br>Miyoshi M, Suzuki K. Elotuzumab plus pomalidomide\/dexamethasone for the treatment of<br>relapsed\/refractory multiple myeloma: Japanese subanalysis of the randomized phase 2<br>ELOQUENT-3 study. 61st American Society of Hematology Annual Meeting &amp; Exposition, 2018<br>Dec 7-10 (San Diego)<\/li>\n\n\n\n<li>Kudo D, Komeno T, Yoshida C, Tsutsumi I, Ohashi K, Kakihana K, Kobayashi T, Doki N, Najima<br>Y, Igarashi A, Hori M, Okoshi Y, Fujio T, Shinagawa A, Yamamoto M, Takano H, Kumagai T,<br>Yamamoto K, Toyota S, Nakamura Y, Kojima H. Efficacy and safety of onceweekly<br>cyclophosphamide-bortezomib-dexamethasone (CBD) regimen as induction therapy prior to<br>autologous stem cell transplantation in Japanese patients with newly diagnosed multiple myeloma. &#8211;<br>a phase 2 multicenter trial-. 61st American Society of Hematology Annual Meeting &amp; Exposition,<br>2018 Dec 7-10 (San Diego)<\/li>\n\n\n\n<li>Hori M, Ohta k, Handa H, Kinoshita G, Shelat S, Miyoshi M, Takezako N, Kubo K.Elotuzumab plus<br>lenalidomide\/dexamethasone (ELd) vs Ld in patients with newly diagnosed multiple myeloma: phase<br>2, randomized, open-label study in Japan.\u65e5\u672c\u9aa8 \u9ac4\u816b\u5b66\u4f1a,2018.5(\u6771\u4eac)<\/li>\n\n\n\n<li>Dimopoulos MA, Dytfeld D, Grosicki S, Moreau P, Takezako N, Hori M, Leleu X, LeBlanc R, Suzuki<br>K, Raab MS, Richardson PG, McKiver MP, Jou Y-M, Shelat SG, Robbins M, Rafferty B, Miguel JS.<br>Elotuzumab plus pomalidomide\/dexamethasone (PD) VS PD for treatment of relapsed\/refractory<br>multiple myeloma: results from the phase 2, randomized open-label eloquent-3 study.23rd European<br>Hematology Association Annual Meeting, June 14\u201317, 2018; Stockholm, Sweden<\/li>\n<\/ol>\n\n\n\n<p>\u3010\u8b1b\u6f14\u3011<\/p>\n\n\n\n<ol class=\"wp-block-list\">\n<li>\u65e5\u5e38\u7684\u306a\u89b3\u8840\u51e6\u7f6e\u306b\u304a\u3051\u308b\u6ce8\u610f\u70b9\u3001\u304a\u3088\u3073\u8840\u6db2\u5185\u79d1\u5074\u304b\u3089\u6b6f\u79d1\u3078\u306e\u63d0\u8a00\u30012018.9 (\u6c34\u6238)<\/li>\n<\/ol>\n\n\n\n<h3 class=\"wp-block-heading\">\u5e73\u621029\u5e74\u5ea6<\/h3>\n\n\n\n<p>\u3010\u5b66\u4f1a\u767a\u8868\u3011<\/p>\n\n\n\n<ol class=\"wp-block-list\">\n<li>Mitsuo Hori, Kensuke Ohta, Hiroshi Handa, Gen Kinoshita, Suresh Shelat,&nbsp; Masafumi Miyoshi, Naoki Takezako, Kohmei Kubo.Elotuzumab Plus Lenalidomide\/Dexamethasone (ELd) vs Ld in Patients With Newly Diagnosed Multiple Myeloma: Phase 2, Randomized, Open-Label Study in Japan \u30a2\u30e1\u30ea\u30ab\u8840\u6db2\u5b66\u4f1a\u7dcf\u4f1a\u30012017\u5e7412\u6708\uff08\u30a2\u30c8\u30e9\u30f3\u30bf\uff09<\/li>\n\n\n\n<li>Hidekatsu IHA, Emi IKEBE, Shunsuke SHIMOSAKI, Fife NICHOLE, Mitsuo HORI, Hiroo HASEGAWA and Kazuhiro MORISHITA. Lenalidomide-mediated growth inhibition of various ATL cells: Cereblon-IKZF transcription factors. \u7b2c79\u56de\u65e5\u672c\u8840\u6db2\u5b66\u4f1a\u5b66\u8853\u7dcf\u4f1a\u30012017\u5e7410\u670820\u65e5\uff08\u6771\u4eac\uff09<\/li>\n\n\n\n<li>Mitsuo Hori, Emi Ikebe Lindsay Sydney FAJARDO, Hiroshi Kojima, Taichi IKEBE, Hidekatsu Iha. Evidences of SLAMF7 expression among multiple lineages of hematologic malignancies: new paths for clinical application. \u30ea\u30f3\u30d1\u7cfb\u816b\u760d\u306b\u304a\u3051\u308b\u306bSLAMF-7\u306e\u767a\u73fe\u306b\u3064\u3044\u3066. \u7b2c79\u56de\u65e5\u672c\u8840\u6db2\u5b66\u4f1a\u5b66\u8853\u7dcf\u4f1a\u30012017\u5e7410\u670820\u65e5\uff08\u6771\u4eac\uff09<\/li>\n<\/ol>\n\n\n\n<h3 class=\"wp-block-heading\">\u5e73\u621028\u5e74\u5ea6<\/h3>\n\n\n\n<p>\u3010\u8ad6\u6587\u3011<\/p>\n\n\n\n<ol class=\"wp-block-list\">\n<li>Fukushima M, Okoshi Y , Fukazawa K , Koshino M, Ishiguro S, Mitsuhashi S , Saitoh H , Iijima T , Kojima H, Hori M . Lymphoplasmacytic lymphoma presenting with diarrhea and joint pain which was successfully <br>diagnosed by an MYD88 mutation analysis . Intern Med . 56 ( 7 ) : 847 &#8211; 851 ,2017 .<\/li>\n<\/ol>\n\n\n\n<p>\u3010\u5b66\u4f1a\u767a\u8868\u3011<\/p>\n\n\n\n<ol class=\"wp-block-list\">\n<li>Mitsuo Hori, Yasushi Okoshi , Takayuki Fujio , Hiroshi Kojima, Hidekatsu Iha , Emi Ikebe. Modulated <br>m RNA expression profiles of a multiple myeloma cell after along-term exposure to lenalidomide. \u7b2c78\u56de \u65e5 \u672c\u8840\u6db2\u5b66\u4f1a\u5b66\u8853\u96c6\u4f1a2016 .10 ( \u6a2a\u6d5c )<\/li>\n<\/ol>\n","protected":false},"excerpt":{"rendered":"<p>\u5e73\u621028\u5e74\u5ea6\uff5e\u4ee4\u548c6\u5e74\u5ea6 \u4ee4\u548c6\u5e74\u5ea6 \u3010\u8ad6\u6587\u3011 \u3010\u5b66\u4f1a\u767a\u8868\u3011 \u4ee4\u548c5\u5e74\u5ea6 \u3010\u8457\u66f8\u3011 \u3010\u8ad6\u6587\u3011 \u4ee4\u548c4\u5e74\u5ea6 \u3010\u8457\u66f8\u3011 \u3010\u8ad6\u6587\u3011 \u3010\u5b66\u4f1a\u767a\u8868\u3011 \u4ee4\u548c3\u5e74\u5ea6 \u3010\u8ad6\u6587\u3011 \u3010\u5b66\u4f1a\u767a\u8868\u3011 \u4ee4\u548c2\u5e74\u5ea6 \u3010\u8ad6\u6587\u3011 \u3010\u5b66\u4f1a\u767a\u8868\u3011 \u3010\u8b1b\u6f14\u3011 [&hellip;]<\/p>\n","protected":false},"author":3,"featured_media":0,"parent":747,"menu_order":1,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_acf_changed":false,"vk-ltc-link":"","vk-ltc-target":"0","footnotes":""},"class_list":["post-16617","page","type-page","status-publish","hentry"],"acf":[],"_links":{"self":[{"href":"https:\/\/www.hospital.pref.ibaraki.jp\/chuo\/wp-json\/wp\/v2\/pages\/16617","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.hospital.pref.ibaraki.jp\/chuo\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.hospital.pref.ibaraki.jp\/chuo\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.hospital.pref.ibaraki.jp\/chuo\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/www.hospital.pref.ibaraki.jp\/chuo\/wp-json\/wp\/v2\/comments?post=16617"}],"version-history":[{"count":5,"href":"https:\/\/www.hospital.pref.ibaraki.jp\/chuo\/wp-json\/wp\/v2\/pages\/16617\/revisions"}],"predecessor-version":[{"id":25085,"href":"https:\/\/www.hospital.pref.ibaraki.jp\/chuo\/wp-json\/wp\/v2\/pages\/16617\/revisions\/25085"}],"up":[{"embeddable":true,"href":"https:\/\/www.hospital.pref.ibaraki.jp\/chuo\/wp-json\/wp\/v2\/pages\/747"}],"wp:attachment":[{"href":"https:\/\/www.hospital.pref.ibaraki.jp\/chuo\/wp-json\/wp\/v2\/media?parent=16617"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}